Cagrilintide
is a
once-weekly investigational medication developed by Novo Nordisk that mimics
amylin, a natural hormone that regulates appetite and blood sugar.
Currently in late-stage clinical trials, it is often combined with semaglutide
(CagriSema), a therapy that has demonstrated significant weight loss.
